Cart
sales@molnova.com
LY450108
CAS No. 376594-67-1
LY450108( —— )
Catalog No. M29625 CAS No. 376594-67-1
LY450108 is a potentiator of the AMPA receptor that can be used in Parkinson's disease studies.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 39 | In Stock |
|
| 5MG | 35 | In Stock |
|
| 10MG | 57 | In Stock |
|
| 25MG | 98 | In Stock |
|
| 50MG | 145 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameLY450108
-
NoteResearch use only, not for human use.
-
Brief DescriptionLY450108 is a potentiator of the AMPA receptor that can be used in Parkinson's disease studies.
-
DescriptionLY450108 is a potentiator of the AMPA receptor that can be used in Parkinson's disease studies.
-
In VitroAMPA receptors mediate most of the excitatory neurotransmission and play a key role in synaptic plasticity in the mammalian central nervous system (CNS). Recent evidence has shown that in addition to modulating fast synaptic plasticity and memory processes, AMPA receptor potentiators alter downstream signalling pathways and may thereby have utility in other CNS disorders.
-
In Vivo——
-
Synonyms——
-
PathwayMembrane Transporter/Ion Channel
-
TargetiGluR
-
RecptoriGluR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number376594-67-1
-
Formula Weight396.45
-
Molecular FormulaC19H22F2N2O3S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : ≥ 50 mg/mL (126.12 mM)
-
SMILESCC(C)S(NC[C@H](C)c(cc1)ccc1NC(c1cc(F)cc(F)c1)=O)(=O)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
CFM-2
CFM-2, a potent and selective non-competitive antagonist of AMPAR (AMPAR), exhibits anticonvulsant activity across various seizure models.
-
Rislenemdaz hydrochl...
Rislenemdaz (MK 0657;CERC 301) is a potent, orally bioavailable, brain‐penetrant, NR2B-selective NMDA receptor (GluN2B) antagonist with Ki and IC 50 of 8.1 nM and 3.6 nM respectively.
-
Rislenemdaz mesylate
Rislenemdaz (MK 0657;CERC 301) is a potent, orally bioavailable, brain‐penetrant, NR2B-selective NMDA receptor (GluN2B) antagonist with Ki and IC 50 of 8.1 nM and 3.6 nM respectively.
